Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT02022540 is registered in ClinicalTrials.gov with PanOptica, Inc. as lead sponsor.

NCT NCT02022540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02022540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Lead sponsor
PanOptica, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2014
Completion date
May 31, 2016
Enrollment
50 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration (amd)